title: Continuing erythropoietin during peripheral blood stem cell collection in myeloma: can it reduce toxicity of autologous transplants?
authors.forename: Laura
authors.initials: L
authors.lastname: Labonté
authors.forename: Tariq
authors.initials: T
authors.lastname: Iqbal
authors.forename: Sheryl
authors.initials: S
authors.lastname: McDiarmid
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bence-Bruckler
authors.forename: Lothar
authors.initials: L
authors.lastname: Huebsch
authors.forename: David
authors.initials: D
authors.lastname: Allan
mesh_terms: D000328:Adult; D000368:Aged; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006454:Hemoglobins / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D011994:Recombinant Proteins; D014182:Transplantation, Autologous / Q000009:adverse effects / Q000379:methods
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin